» Articles » PMID: 15264249

Pim-1 Expression in Prostatic Intraepithelial Neoplasia and Human Prostate Cancer

Overview
Journal Prostate
Date 2004 Jul 21
PMID 15264249
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Background: PIM-1, an oncogene product of serine/threonine kinase, has been found to play an important role in induction/suppression of apoptosis, cell cycle progression, and transcriptional regulation by phosphorylating the target proteins involved in these processes. Recently, the expression of PIM-1 has been shown to correlate significantly with measures of prostate cancer clinical outcome.

Methods: Immunohistochemical analysis was used to characterize the patterns of PIM-1 expression in high grade prostatic intraepithelial neoplasia (HGPIN) and cancer in 121 radical prostatectomy specimens.

Results: Moderate to strong cytoplasmic staining was observed in 68% of cancers, 12% presented nuclear positivity as well. Moderate to strong expression was seen in 76% of tumors with Gleason score (GS) 7 or higher compared to 58% in tumors with GS 6 or lower (P = 0.04). The staining intensity was moderate or strong in 97% of HGPIN lesions. PIM-1 was overexpressed in HGPIN compared to cancer in 65% of cases. Expression in benign glands was negative or only weakly positive.

Conclusion: Our data suggest that PIM-1 overexpression in HGPIN may be an early event in the development of prostate malignancy. Additionally, PIM-1 expression provides supplementary information for distinguishing HGPIN from benign epithelium.

Citing Articles

An experimental and computational investigation of the cyclopentene-containing peptide-derived compounds: focus on pseudo-cyclic motifs via intramolecular interactions.

Bojarska J, Breza M, Borowiecki P, Madura I, Kaczmarek K, Ziora Z R Soc Open Sci. 2024; 11(10):40962.

PMID: 39386982 PMC: 11462612. DOI: 10.1098/rsos.240962.


Regulating Androgen Receptor Function in Prostate Cancer: Exploring the Diversity of Post-Translational Modifications.

Lumahan L, Arif M, Whitener A, Yi P Cells. 2024; 13(2).

PMID: 38275816 PMC: 10814774. DOI: 10.3390/cells13020191.


Synthesis and Anticancer Activity of Novel Dual Inhibitors of Human Protein Kinases CK2 and PIM-1.

Winska P, Wielechowska M, Koronkiewicz M, Borowiecki P Pharmaceutics. 2023; 15(7).

PMID: 37514177 PMC: 10385865. DOI: 10.3390/pharmaceutics15071991.


PIM1/STAT3 axis: a potential co-targeted therapeutic approach in triple-negative breast cancer.

Mahata S, Sahoo P, Pal R, Sarkar S, Mistry T, Ghosh S Med Oncol. 2022; 39(5):74.

PMID: 35568774 DOI: 10.1007/s12032-022-01675-2.


Context-Specific Efficacy of Apalutamide Therapy in Preclinical Models of -Deficient Prostate Cancer.

De Velasco M, Kura Y, Ando N, Sako N, Banno E, Fujita K Cancers (Basel). 2021; 13(16).

PMID: 34439133 PMC: 8391912. DOI: 10.3390/cancers13163975.